Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

INTRODUCTION: In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization’s elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for H...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Infect Dis Ther
Autors principals: Andreoni, Massimo, Di Perri, Giovanni, Persico, Marcello, Marcellusi, Andrea, Ethgen, Olivier, Sanchez Gonzalez, Yuri, Bondin, Mark, Zhang, Zhenzhen, De Michina, Antonella, Merolla, Rocco Cosimo Damiano, Craxì, Antonio
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7925258/
https://ncbi.nlm.nih.gov/pubmed/33655410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-021-00410-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars